149 related articles for article (PubMed ID: 15733368)
21. In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
Giovanetti E; Montanari MP; Marchetti F; Varaldo PE
J Antimicrob Chemother; 2000 Dec; 46(6):905-8. PubMed ID: 11102408
[TBL] [Abstract][Full Text] [Related]
22. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting.
Alós JI; Aracil B; Oteo J; Torres C; Gómez-Garcés JL
J Antimicrob Chemother; 2000 May; 45(5):605-9. PubMed ID: 10797081
[TBL] [Abstract][Full Text] [Related]
23. Macrolide resistance in Belgian Streptococcus pneumoniae.
Lagrou K; Peetermans WE; Verhaegen J; Van Lierde S; Verbist L; Van Eldere J
J Antimicrob Chemother; 2000 Jan; 45(1):119-21. PubMed ID: 10629023
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and mechanisms of erythromycin resistance in group A and group B Streptococcus: implications for reporting susceptibility results.
Desjardins M; Delgaty KL; Ramotar K; Seetaram C; Toye B
J Clin Microbiol; 2004 Dec; 42(12):5620-3. PubMed ID: 15583291
[TBL] [Abstract][Full Text] [Related]
25. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae.
Jorgensen JH; Swenson JM; Tenover FC; Barry A; Ferraro MJ; Murray PR; Reller LB
J Clin Microbiol; 1996 Nov; 34(11):2679-84. PubMed ID: 8897164
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae.
Johnston NJ; De Azavedo JC; Kellner JD; Low DE
Antimicrob Agents Chemother; 1998 Sep; 42(9):2425-6. PubMed ID: 9736575
[TBL] [Abstract][Full Text] [Related]
27. Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania.
Green M; Martin JM; Barbadora KA; Beall B; Wald ER
Antimicrob Agents Chemother; 2004 Feb; 48(2):473-6. PubMed ID: 14742197
[TBL] [Abstract][Full Text] [Related]
28. Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents.
Ednie LM; Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 May; 41(5):1033-6. PubMed ID: 9145864
[TBL] [Abstract][Full Text] [Related]
29. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.
Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Feb; 44(2):414-7. PubMed ID: 10639373
[TBL] [Abstract][Full Text] [Related]
30. Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa.
Widdowson CA; Klugman KP
Emerg Infect Dis; 1998; 4(2):277-81. PubMed ID: 9621199
[TBL] [Abstract][Full Text] [Related]
31. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.
Ednie LM; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1950-2. PubMed ID: 8843313
[TBL] [Abstract][Full Text] [Related]
32. Microbiologic activity of the newer macrolide antibiotics.
McCracken GH
Pediatr Infect Dis J; 1997 Apr; 16(4):432-7. PubMed ID: 9109155
[TBL] [Abstract][Full Text] [Related]
33. Clindamycin resistance among erythromycin-resistant Streptococcus pneumoniae.
Jones RN; Cormican MG; Wanger A
Diagn Microbiol Infect Dis; 1996 Aug; 25(4):201-4. PubMed ID: 8937845
[TBL] [Abstract][Full Text] [Related]
34. Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy.
Marchese A; Tonoli E; Debbia EA; Schito GC
J Antimicrob Chemother; 1999 Oct; 44(4):461-4. PubMed ID: 10588306
[TBL] [Abstract][Full Text] [Related]
35. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates.
Oster P; Zanchi A; Cresti S; Lattanzi M; Montagnani F; Cellesi C; Rossolini GM
Antimicrob Agents Chemother; 1999 Oct; 43(10):2510-2. PubMed ID: 10508033
[TBL] [Abstract][Full Text] [Related]
36. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae.
Tait-Kamradt A; Clancy J; Cronan M; Dib-Hajj F; Wondrack L; Yuan W; Sutcliffe J
Antimicrob Agents Chemother; 1997 Oct; 41(10):2251-5. PubMed ID: 9333056
[TBL] [Abstract][Full Text] [Related]
37. Antipneumococcal activity of ABT-773 compared to those of 10 other agents.
Davies TA; Ednie LM; Hoellman DM; Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Jul; 44(7):1894-9. PubMed ID: 10858350
[TBL] [Abstract][Full Text] [Related]
38. High proportion of pharyngeal carriers of commensal streptococci resistant to erythromycin in Spanish adults.
Pérez-Trallero E; Vicente D; Montes M; Marimon JM; Piñeiro L
J Antimicrob Chemother; 2001 Aug; 48(2):225-9. PubMed ID: 11481292
[TBL] [Abstract][Full Text] [Related]
39. Novel mechanism of macrolide resistance in Streptococcus pneumoniae.
Shortridge VD; Flamm RK; Ramer N; Beyer J; Tanaka SK
Diagn Microbiol Infect Dis; 1996 Oct; 26(2):73-8. PubMed ID: 8985659
[TBL] [Abstract][Full Text] [Related]
40. Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA.
Barry AL; Fuchs PC; Brown SD
J Antimicrob Chemother; 1997 Jul; 40(1):139-40. PubMed ID: 9249220
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
